Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 3
This from Egoli-

SHAW Analyst Comments: Resmed's Q4 and FY

August 14, 2002

Q4 and FY result

Resmed (RMD) released their Q4 and FY result to the market this morning local
time. Full year revenue increased 32% to US$204.1M (SHAW expectations
were for revenue of $204.8M). Net Income increased 222% to US$37.5M
(SHAW expectations of $36.0M). US sales increased 27% which appears to be
ahead of the market growth rate, while international sales increased 13%.
German sales increased 10% on the March quarter, with prescription volumes
growing. There is a longer than usual delay in German between prescriptions
and recognition of revenue - thus a lagging effect on evidence of recovery in
that country. No dividend was declared. Regarding the share buy-back: only
290,047 shares of a total 4M shares have been repurchased to date, leaving
room for further share price support.

Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.